Novo Nordisk Research Centre Oxford is an innovative target discovery unit with a focus on identifying novel, game-changing therapies for patients with type 2 diabetes and cardiometabolic diseases.

We employ advanced computational biology, state-of-the-art discovery screening technologies, genetics and human-centric cell systems to dissect pathophysiology and identify novel drug targets. The site is a fusion of the best of academia, biotech and big pharma in order to realize cutting-edge biology and start a target’s journey from bench to bedside.

NNRCO operates at the boundaries of frontier science with a mandate to find dynamic, agile and distinctive new ways of working to diversify the company’s pipeline with disruptive medicines.

Our Research Centre Oxford continuously looks for partners with expertise in type 2 diabetes and cardiometabolic diseases, from novel modalities to technologies, in early research to clinical stage.

We are interested in academic and industrial partners who use disruptive technologies to challenge traditional ways of thinking and benefit unmet patient needs. We offer partners our disease understanding, human-centric scientific models, state-of-the-art technologies and tailored collaborations.

Contact us to engage with us:

We describe ourselves as collaborative, dedicated and ambitious, with an innovative science-oriented approach to drive change to improve patient’s lives. We are a diverse group with backgrounds in bioinformatics, genetics, disease biology, technology and drug discovery.

Our workplace values and culture are spelled out in The Novo Nordisk Way.

Visit our careers page to find opportunities to join our team.

Oxford lab employee

Our Oxford Fellowship Programme is run in close collaboration with the University of Oxford.

The programme supports the development of a new generation of exceptional diabetes and metabolism researchers, who will become future leaders in the field, while further advancing scientific excellence within diabetes and cardiometabolic diseases.

The programme has approximately five highly competitive research and clinical research training fellow positions available each year. 

Visit the programme website for open positions and to learn more about current and past fellows.

To identify novel targets and add value to other research projects, our teams are using in silico pipelines, novel algorithms and advanced machine learning activities. We achieve this by utilizing state-of-the-art data integration pipelines to analyze large scale data (e.g. clinical biobanks, GTEX, and all types of omics) that are generated by in-house experiments and external collaborators. We then use cloud based computational and flexible environments. Collaborations are an essential part of the group, to strengthen our research for the benefit of patients. Our current partnerships are with academic groups and biotechs.

Department head: Ramneek Gupta

We establish and apply state-of-the-art genomics and screening technologies to discover and validate novel therapeutic targets for cardiometabolic diseases using human-centric in vitro approaches. Our technologies include high throughput screening, high content imaging, single-cell sequencing, CRISPR editing, functional genomics, proteomics, peptidomics, and statistical modelling. By applying these technologies to human samples and human centric in vitro models, we interrogate disease pathogenesis, elucidate the function of genes and proteins, and identify targets and key biology to discover new disruptive therapeutics.

Department head: Thomas Meek

We utilize cutting-edge technologies to follow research hypotheses from gene, to cell, to tissue, to organ cross-talk, to organism. To do this we capitalize upon stem cell biology, CRISPR and other genome engineering techniques, in vitro differentiation and multi-parametric cellular assays. We plan to extend the complexity of our systems using bioprinting and organ-on-a-chip technologies going forward. Our cellular studies focus on capturing physiologically-representative function and phenotypes to push the boundaries of translational research to validate novel targets in complex systems that mimic human tissues.

Department head: Carina Ämmälä

The Genetics Department generates and applies human genetics knowledge to improve drug target prioritisation by identifying novel targets and biomarkers, their tissue/cell-specific expression and potential contra-indications. We utilize approaches such as patient stratification from genetic risk scores for precision medicine; Mendelian Randomization screens for identifying causal risk factors for cardiometabolic diseases; perform in silico screens to go from associated variants to causal genes. In tandem with these approaches, we perform phenotypic screens to identify contraindications for any potential targets we identify. We work with the Discovery Technologies and Genomics Department and the Discovery Biology and Pharmacology Department to obtain in vitro validation of our candidate targets.

Department head: Joanna Howson

Research teams are supported by a lean operations team, covering an array of business functions, such as lab and facilities, research IT, procurement, human resources and finance. We strive to provide best in class services.

Department head: Tore Karlsson